PT0511

PAQ Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	PT0511
Sponsor	PAQ Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PT0511 CI brief — competitive landscape report
PT0511 updates RSS · CI watch RSS
PAQ Therapeutics, Inc. portfolio CI